NO327727B1 - Fremgangsmate for revers transkribering og deteksjon av HIV-RNA i en biologisk prove, oligonukleotid og kit. - Google Patents
Fremgangsmate for revers transkribering og deteksjon av HIV-RNA i en biologisk prove, oligonukleotid og kit. Download PDFInfo
- Publication number
- NO327727B1 NO327727B1 NO20000513A NO20000513A NO327727B1 NO 327727 B1 NO327727 B1 NO 327727B1 NO 20000513 A NO20000513 A NO 20000513A NO 20000513 A NO20000513 A NO 20000513A NO 327727 B1 NO327727 B1 NO 327727B1
- Authority
- NO
- Norway
- Prior art keywords
- hiv
- rna
- reverse transcription
- amplification
- detection
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 46
- 238000010839 reverse transcription Methods 0.000 title claims abstract description 41
- 238000001514 detection method Methods 0.000 title claims abstract description 27
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 21
- 239000012472 biological sample Substances 0.000 title claims abstract description 17
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 55
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 50
- 230000003321 amplification Effects 0.000 claims description 49
- 239000000523 sample Substances 0.000 claims description 20
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 14
- 238000003752 polymerase chain reaction Methods 0.000 claims description 13
- 208000031886 HIV Infections Diseases 0.000 claims description 12
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 10
- 210000002381 plasma Anatomy 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 8
- 238000001502 gel electrophoresis Methods 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- 239000002299 complementary DNA Substances 0.000 claims description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 238000007834 ligase chain reaction Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000006073 displacement reaction Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 238000002038 chemiluminescence detection Methods 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 239000013615 primer Substances 0.000 description 68
- 150000007523 nucleic acids Chemical class 0.000 description 19
- 108020004707 nucleic acids Proteins 0.000 description 14
- 102000039446 nucleic acids Human genes 0.000 description 14
- 102100034349 Integrase Human genes 0.000 description 13
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 8
- 239000011543 agarose gel Substances 0.000 description 6
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 6
- 229960005542 ethidium bromide Drugs 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 238000004737 colorimetric analysis Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000713869 Moloney murine leukemia virus Species 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- -1 phosphotriesters Chemical class 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- CZVCGJBESNRLEQ-UHFFFAOYSA-N 7h-purine;pyrimidine Chemical compound C1=CN=CN=C1.C1=NC=C2NC=NC2=N1 CZVCGJBESNRLEQ-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101000650854 Homo sapiens Small glutamine-rich tetratricopeptide repeat-containing protein alpha Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 101710149136 Protein Vpr Proteins 0.000 description 1
- 239000012162 RNA isolation reagent Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 101710201961 Virion infectivity factor Proteins 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- DGMKFQYCZXERLX-UHFFFAOYSA-N proglumide Chemical compound CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)C1=CC=CC=C1 DGMKFQYCZXERLX-UHFFFAOYSA-N 0.000 description 1
- 229960003857 proglumide Drugs 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- AIDS & HIV (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11841799P | 1999-02-02 | 1999-02-02 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20000513D0 NO20000513D0 (no) | 2000-02-01 |
| NO20000513L NO20000513L (no) | 2000-08-03 |
| NO327727B1 true NO327727B1 (no) | 2009-09-14 |
Family
ID=22378462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20000513A NO327727B1 (no) | 1999-02-02 | 2000-02-01 | Fremgangsmate for revers transkribering og deteksjon av HIV-RNA i en biologisk prove, oligonukleotid og kit. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6303293B1 (es) |
| EP (1) | EP1026263B1 (es) |
| JP (1) | JP2000342274A (es) |
| KR (1) | KR100901084B1 (es) |
| CN (1) | CN1186455C (es) |
| AT (1) | ATE397099T1 (es) |
| AU (1) | AU761066B2 (es) |
| CA (1) | CA2295920C (es) |
| DE (1) | DE60038993D1 (es) |
| DK (1) | DK1026263T3 (es) |
| ES (1) | ES2306648T3 (es) |
| NO (1) | NO327727B1 (es) |
| PT (1) | PT1026263E (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8036741B2 (en) | 1996-04-30 | 2011-10-11 | Medtronic, Inc. | Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure |
| US6479523B1 (en) * | 1997-08-26 | 2002-11-12 | Emory University | Pharmacologic drug combination in vagal-induced asystole |
| EP1198271A4 (en) | 1999-06-25 | 2009-01-21 | Univ Emory | DEVICES AND METHODS FOR STIMULATING THE VAGUSNERVS |
| US6623920B1 (en) * | 1999-07-09 | 2003-09-23 | Gen-Probe Incorporated | Detection of HIV-1 by nucleic acid amplification |
| CA2318730C (en) * | 1999-09-20 | 2008-01-22 | Ortho-Clinical Diagnostics, Inc. | A method for reverse transcribing rna isolated in dry form |
| DE60132924T2 (de) | 2000-10-23 | 2009-03-05 | Gen-Probe Inc., San Diego | Zusammensetzungen und methoden zur detektion von humanem immundefizienz virus 2 (hiv-2) |
| EP2251442B9 (en) * | 2003-12-19 | 2012-04-25 | Gen-Probe Incorporated | Compositions, methods and kits for detecting the nucleic acids of HIV-1 and HIV-2 |
| CN100340673C (zh) * | 2005-02-03 | 2007-10-03 | 上海科华生物工程股份有限公司 | 人类免疫缺陷病毒hiv－1核酸扩增－荧光定量检测试剂盒 |
| GB0701253D0 (en) | 2007-01-23 | 2007-02-28 | Diagnostics For The Real World | Nucleic acid amplification and testing |
| EP3187585A1 (en) | 2010-03-25 | 2017-07-05 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
| US8639327B2 (en) | 2010-04-29 | 2014-01-28 | Medtronic, Inc. | Nerve signal differentiation in cardiac therapy |
| US8423134B2 (en) | 2010-04-29 | 2013-04-16 | Medtronic, Inc. | Therapy using perturbation and effect of physiological systems |
| US8620425B2 (en) | 2010-04-29 | 2013-12-31 | Medtronic, Inc. | Nerve signal differentiation in cardiac therapy |
| US8706223B2 (en) | 2011-01-19 | 2014-04-22 | Medtronic, Inc. | Preventative vagal stimulation |
| US8781583B2 (en) | 2011-01-19 | 2014-07-15 | Medtronic, Inc. | Vagal stimulation |
| US8718763B2 (en) | 2011-01-19 | 2014-05-06 | Medtronic, Inc. | Vagal stimulation |
| US8725259B2 (en) | 2011-01-19 | 2014-05-13 | Medtronic, Inc. | Vagal stimulation |
| US8781582B2 (en) | 2011-01-19 | 2014-07-15 | Medtronic, Inc. | Vagal stimulation |
| DK2691530T3 (en) | 2011-06-10 | 2018-05-22 | Univ Oregon Health & Science | CMV GLYCOPROTEIN AND RECOMBINANT VECTORS |
| EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| CN104066842A (zh) * | 2012-01-25 | 2014-09-24 | 独立行政法人科学技术振兴机构 | Hiv检测用寡核苷酸、hiv检测试剂盒及hiv检测方法 |
| EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
| EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
| EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| ES2800474T3 (es) * | 2014-05-27 | 2020-12-30 | Univ Paris Descartes | Método in vitro para la detección y la cuantificación del VIH-2 |
| US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| AU2017301881A1 (en) * | 2016-07-29 | 2019-02-07 | Juno Therapeutics, Inc. | Methods for assessing the presence or absence of replication competent virus |
| CA3035808A1 (en) * | 2016-09-07 | 2018-03-15 | St Vincent's Hospital Sydney Limited | Methods of detecting lentivirus |
| CN106498095A (zh) * | 2016-11-14 | 2017-03-15 | 湖南圣湘生物科技有限公司 | 一种人类免疫性缺陷病毒2型核酸检测试剂盒 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69034220T2 (de) | 1989-06-02 | 2006-12-28 | Institut Pasteur | Nukleotid-Sequenzen von HIV-1, HIV-2 and SIV Retrovirusgenommen, ihre Verwendung zur Amplifizierung von diesen Retrovieren und zur in vitro Diagnostik von diesen Viren verursachten Infektion |
| US5478724A (en) | 1991-08-16 | 1995-12-26 | The Rockefeller University | Lentivirus-specific nucleotide probes and methods of use |
| AU677225B2 (en) | 1992-10-06 | 1997-04-17 | Dade Behring Marburg Gmbh | Retrovirus from the HIV group and its use |
| US5599662A (en) * | 1995-02-17 | 1997-02-04 | Hoffmann-La Roche Inc. | Oliconucleotide primers and probes for the detection of HIV-1 |
| US5962665A (en) | 1997-06-16 | 1999-10-05 | Abbott Laboratories | Nucleic acid primers and probes for detecting HIV-1 and HIV-2 |
| US6001558A (en) * | 1997-06-25 | 1999-12-14 | Ortho Clinical Diagnostics, Inc. | Amplification and detection of HIV-1 and/or HIV 2 |
-
2000
- 2000-01-28 US US09/494,102 patent/US6303293B1/en not_active Expired - Lifetime
- 2000-02-01 AU AU14829/00A patent/AU761066B2/en not_active Ceased
- 2000-02-01 DK DK00300792T patent/DK1026263T3/da active
- 2000-02-01 EP EP00300792A patent/EP1026263B1/en not_active Expired - Lifetime
- 2000-02-01 NO NO20000513A patent/NO327727B1/no not_active IP Right Cessation
- 2000-02-01 PT PT00300792T patent/PT1026263E/pt unknown
- 2000-02-01 CA CA2295920A patent/CA2295920C/en not_active Expired - Fee Related
- 2000-02-01 DE DE60038993T patent/DE60038993D1/de not_active Expired - Lifetime
- 2000-02-01 ES ES00300792T patent/ES2306648T3/es not_active Expired - Lifetime
- 2000-02-01 AT AT00300792T patent/ATE397099T1/de active
- 2000-02-02 KR KR1020000005148A patent/KR100901084B1/ko not_active IP Right Cessation
- 2000-02-02 JP JP2000025419A patent/JP2000342274A/ja active Pending
- 2000-02-02 CN CNB001053973A patent/CN1186455C/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE397099T1 (de) | 2008-06-15 |
| KR20010014470A (ko) | 2001-02-26 |
| DK1026263T3 (da) | 2008-09-08 |
| ES2306648T3 (es) | 2008-11-16 |
| EP1026263A3 (en) | 2000-10-11 |
| CN1186455C (zh) | 2005-01-26 |
| DE60038993D1 (de) | 2008-07-10 |
| EP1026263B1 (en) | 2008-05-28 |
| AU1482900A (en) | 2000-08-03 |
| EP1026263A2 (en) | 2000-08-09 |
| JP2000342274A (ja) | 2000-12-12 |
| CA2295920A1 (en) | 2000-08-02 |
| NO20000513D0 (no) | 2000-02-01 |
| CN1271020A (zh) | 2000-10-25 |
| AU761066B2 (en) | 2003-05-29 |
| CA2295920C (en) | 2013-10-29 |
| NO20000513L (no) | 2000-08-03 |
| KR100901084B1 (ko) | 2009-06-08 |
| PT1026263E (pt) | 2008-08-27 |
| US6303293B1 (en) | 2001-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO327727B1 (no) | Fremgangsmate for revers transkribering og deteksjon av HIV-RNA i en biologisk prove, oligonukleotid og kit. | |
| Fouchier et al. | Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR | |
| US6638714B1 (en) | Oligonucleotide primers for efficient detection of hepatitis C virus (HCV) and methods of use thereof | |
| EP1422298B1 (en) | Detection of hiv-1 by nucleic acid amplification | |
| EP2390259B1 (en) | Amplification and detection reagents for HIV-1 | |
| US8575324B2 (en) | Methods and reagents for molecular detection of HIV-1 groups M, N and O | |
| EP3214181A1 (en) | Oligonucleotides, set of oligonucleotides, htlv-i/htlv-ii infection diagnostic and discrimination kit, polynucleotide suitable as reference target for designing primers and probes for the detection and differentiation of htlv-i and htlv-ii, amplicon and method for detecting at least one htlv target | |
| US5478724A (en) | Lentivirus-specific nucleotide probes and methods of use | |
| KR100910545B1 (ko) | Ｃ형 간염 바이러스(ｈｃｖ) 및 사람 면역결핍 바이러스(ｈｉｖ)의 효과적인 다중 검출을 위한 올리고뉴클레오티드 프라이머, 이의 이용 방법, 및 이를 포함하는 키트 | |
| CN110945146B (zh) | 检测人类免疫缺陷病毒(hiv)的测定法 | |
| EP0481215A1 (en) | Method for the detection of an HIV-1 genome by a two-step PCR method and oligonucleotide used in the same | |
| EP0756639B1 (en) | Methods for the discrimination between syncytium inducing and non syncytium inducing variants of the human immunodeficiency virus and primers to be used in the methods | |
| WO2000014272A1 (en) | Measurement of persistent-latent hiv viral load | |
| NO329546B1 (no) | Fremgangsmate for reverstranskribering og detektering av HCV-RNA, oligonukleotid egnet for bruk i nevnte fremgangsmate samt kit inneholdende nevnte oligonukleotid. | |
| CA2376609A1 (en) | Method for determining hiv-1 subtype | |
| CA2374385C (en) | Detection of hiv-1 by nucleic acid amplification | |
| González-Villaseñor et al. | A solid phase plate assay for HIV-1 genotyping |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |